Payment overview · 2025
General Payments
$341.65
17 reported records · 12 companies
Healthcare provider profile · identity verified
Jerry A Cohen, D.O.
Allopathic & Osteopathic Physicians|Family Medicine|Geriatric Medicine · NARBERTH, PA · NPI 1629015680
Verified facts
What the public records show
CMS Open Payments records show Jerry A Cohen, D.O. received $341.65 in general payments during 2025 across 17 reported records.
Neurocrine BioSciences, Inc. accounted for 21.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 911 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 135 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABILIFY MAINTENA as an associated drug or biological on 2902 records involving 986 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Abilify Maintena by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABILIFY MAINTENA as an associated drug or biological on 27924 records involving 10497 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Abilify Maintena by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Nuedexta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $74.52 | 21.8% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $55.81 | 16.3% | 3 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$37.45 | 11.0% | 2 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $24.53 | 7.2% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $22.59 | 6.6% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $22.34 | 6.5% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $19.55 | 5.7% | 1 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $17.96 | 5.3% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.81 | 5.2% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $17.58 | 5.2% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $16.18 | 4.7% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $15.33 | 4.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $341.65 | 17 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $78.40 | 4 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $74.52 | 3 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $24.53 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $22.34 | 1 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $19.55 | 1 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $17.96 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $17.81 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $17.58 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $16.18 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $15.33 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
911 | 83 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
58 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
135 | 13 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | ABILIFY MAINTENA open payments reported associated product |
CMS Open Payments — General Payments 2902 supporting records · 986 recipient NPIs · example record 1251759994 |
Abilify Maintena · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | ABILIFY MAINTENA open payments reported associated product |
CMS Open Payments — General Payments 27924 supporting records · 10497 recipient NPIs · example record 1227267721 |
Abilify Maintena · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1465 | 210 |
| Amlodipine Besylate | Amlodipine Besylate | 1209 | 172 |
| Eliquis | Apixaban | 911 | 83 |
| Levothyroxine Sodium | Levothyroxine Sodium | 769 | 71 |
| Furosemide | Furosemide | 682 | 79 |
| Mirtazapine | Mirtazapine | 668 | 94 |
| Gabapentin | Gabapentin | 631 | 96 |
| Risperidone | Risperidone | 554 | 59 |
| Metformin Hcl | Metformin Hcl | 543 | 72 |
| Divalproex Sodium | Divalproex Sodium | 502 | 55 |
| Metoprolol Succinate | Metoprolol Succinate | 477 | 72 |
| Lisinopril | Lisinopril | 471 | 74 |
| Pantoprazole Sodium | Pantoprazole Sodium | 454 | 71 |
| Trazodone Hcl | Trazodone Hcl | 446 | 58 |
| Hydrochlorothiazide | Hydrochlorothiazide | 422 | 60 |
| Metoprolol Tartrate | Metoprolol Tartrate | 387 | 56 |
| Tamsulosin Hcl | Tamsulosin Hcl | 384 | 66 |
| Losartan Potassium | Losartan Potassium | 362 | 55 |
| Sertraline Hcl | Sertraline Hcl | 361 | 45 |
| Clonazepam | Clonazepam | 353 | 56 |
| Escitalopram Oxalate | Escitalopram Oxalate | 350 | 54 |
| Levetiracetam | Levetiracetam | 347 | 45 |
| Benztropine Mesylate | Benztropine Mesylate | 328 | 41 |
| Quetiapine Fumarate | Quetiapine Fumarate | 318 | 33 |
| Haloperidol | Haloperidol | 301 | 28 |
| Olanzapine | Olanzapine | 290 | 39 |
| Clopidogrel | Clopidogrel Bisulfate | 258 | 42 |
| Ibuprofen | Ibuprofen | 256 | 58 |
| Lorazepam | Lorazepam | 244 | 54 |
| Nifedipine Er | Nifedipine | 242 | 49 |
| Aripiprazole | Aripiprazole | 234 | 32 |
| Carvedilol | Carvedilol | 209 | 40 |
| Famotidine | Famotidine | 201 | 44 |
| Baclofen | Baclofen | 196 | 27 |
| Buspirone Hcl | Buspirone Hcl | 194 | 28 |
| Potassium Chloride | Potassium Chloride | 189 | 29 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 183 | 35 |
| Latanoprost | Latanoprost | 180 | 31 |
| Donepezil Hcl | Donepezil Hcl | 178 | 26 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 176 | 27 |
| Fluoxetine Hcl | Fluoxetine Hcl | 169 | 23 |
| Omeprazole | Omeprazole | 157 | 37 |
| Simvastatin | Simvastatin | 154 | 19 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 153 | 22 |
| Xarelto | Rivaroxaban | 152 | 12 |
| Clozapine | Clozapine | 149 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 137 | 23 |
| Trulicity | Dulaglutide | 135 | 13 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 131 | 48 |
| Farxiga | Dapagliflozin Propanediol | 119 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 118 | 18 |
| Bumetanide | Bumetanide | 117 | 17 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 110 | 14 |
| Divalproex Sodium Er | Divalproex Sodium | 106 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 97 | 13 |
| Alendronate Sodium | Alendronate Sodium | 96 | 11 |
| Allopurinol | Allopurinol | 92 | 14 |
| Finasteride | Finasteride | 92 | 12 |
| Januvia | Sitagliptin Phosphate | 92 | suppressed |
| Insulin Lispro | Insulin Lispro | 89 | 28 |
| Humalog | Insulin Lispro | 86 | 24 |
| Citalopram Hbr | Citalopram Hydrobromide | 83 | 12 |
| Enoxaparin Sodium | Enoxaparin Sodium | 77 | suppressed |
| Lacosamide | Lacosamide | 77 | 19 |
| Tramadol Hcl | Tramadol Hcl | 77 | 36 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 76 | 24 |
| Memantine Hcl | Memantine Hcl | 70 | suppressed |
| Celecoxib | Celecoxib | 69 | 13 |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 69 | 11 |
| Ezetimibe | Ezetimibe | 68 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 68 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 67 | 20 |
| Heparin Sodium | Heparin Sodium,porcine | 67 | 11 |
| Amiodarone Hcl | Amiodarone Hcl | 66 | 13 |
| Haloperidol Decanoate | Haloperidol Decanoate | 66 | 12 |
| Propranolol Hcl | Propranolol Hcl | 66 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 65 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 64 | 37 |
| Breo Ellipta | Fluticasone/Vilanterol | 63 | 14 |
| Valsartan | Valsartan | 62 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 61 | 16 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 60 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 59 | 13 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 59 | 19 |
| Jardiance | Empagliflozin | 58 | suppressed |
| Timolol Maleate | Timolol Maleate | 57 | 12 |
| Atenolol | Atenolol | 56 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 56 | 12 |
| Glipizide | Glipizide | 55 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 54 | suppressed |
| Amantadine | Amantadine Hcl | 52 | suppressed |
| Lovastatin | Lovastatin | 50 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 48 | 12 |
| Metformin Hcl Er | Metformin Hcl | 48 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 48 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 47 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 45 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 45 | 13 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 44 | 12 |
| Olanzapine Odt | Olanzapine | 44 | suppressed |
| Lamotrigine | Lamotrigine | 43 | suppressed |
| Haloperidol Lactate | Haloperidol Lactate | 42 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 42 | suppressed |
| Meloxicam | Meloxicam | 41 | suppressed |
| Tradjenta | Linagliptin | 41 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 40 | 15 |
| Anastrozole | Anastrozole | 39 | suppressed |
| Bromocriptine Mesylate | Bromocriptine Mesylate | 39 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 39 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 39 | 18 |
| Spironolactone | Spironolactone | 39 | suppressed |
| Sulfasalazine | Sulfasalazine | 39 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 39 | suppressed |
| Carbamazepine | Carbamazepine | 38 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 38 | 20 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 38 | 11 |
| Prednisone | Prednisone | 37 | 13 |
| Clonidine Hcl | Clonidine Hcl | 36 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 36 | suppressed |
| Gemtesa | Vibegron | 35 | suppressed |
| Glucagon Emergency Kit | Glucagon | 35 | 23 |
| Paroxetine Hcl | Paroxetine Hcl | 35 | suppressed |
| Sucralfate | Sucralfate | 35 | suppressed |
| Alprazolam | Alprazolam | 34 | 12 |
| Cephalexin | Cephalexin | 32 | 19 |
| Bupropion Hcl | Bupropion Hcl | 31 | suppressed |
| Nystatin | Nystatin | 31 | 15 |
| Oxycodone Hcl | Oxycodone Hcl | 31 | 21 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 31 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 30 | 17 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 30 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 30 | 20 |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 30 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 30 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 30 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 30 | suppressed |
| Myrbetriq | Mirabegron | 30 | suppressed |
| Novolog | Insulin Aspart | 30 | suppressed |
| Chlorthalidone | Chlorthalidone | 29 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 29 | suppressed |
| Topiramate | Topiramate | 29 | suppressed |
| Acetylcysteine | Acetylcysteine | 28 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 28 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 28 | 12 |
| Calcitriol | Calcitriol | 27 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 27 | 11 |
| Valproic Acid | Valproic Acid | 27 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 26 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 25 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 25 | suppressed |
| Glipizide Er | Glipizide | 25 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 25 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 25 | suppressed |
| Amoxicillin | Amoxicillin | 24 | 14 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 24 | suppressed |
| Lactulose | Lactulose | 24 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 24 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 23 | suppressed |
| Ketoconazole | Ketoconazole | 23 | 14 |
| Lithium Carbonate Er | Lithium Carbonate | 23 | suppressed |
| Scopolamine | Scopolamine | 23 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 23 | 17 |
| Clonidine | Clonidine | 22 | suppressed |
| Cyclosporine | Cyclosporine | 22 | suppressed |
| Levofloxacin | Levofloxacin | 22 | 13 |
| Linzess | Linaclotide | 22 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 22 | suppressed |
| Loxapine | Loxapine Succinate | 22 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 22 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 22 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 21 | suppressed |
| Digoxin | Digoxin | 21 | suppressed |
| Abilify Maintena | Aripiprazole | 20 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Entresto | Sacubitril/Valsartan | 20 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 20 | suppressed |
| Pregabalin | Pregabalin | 20 | suppressed |
| Travoprost | Travoprost | 20 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 19 | 18 |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 19 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 19 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 19 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 18 | suppressed |
| Bicalutamide | Bicalutamide | 18 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 18 | suppressed |
| Glucagen | Glucagon | 18 | 12 |
| Insulin Aspart | Insulin Aspart | 18 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 18 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 17 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 17 | 11 |
| Ziprasidone Hcl | Ziprasidone Hcl | 17 | suppressed |
| Budesonide | Budesonide | 16 | suppressed |
| Carbamazepine Er | Carbamazepine | 16 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 16 | suppressed |
| Repaglinide | Repaglinide | 16 | suppressed |
| Retacrit | Epoetin Alfa-Epbx | 16 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 16 | suppressed |
| Brinzolamide | Brinzolamide | 15 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 15 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 15 | suppressed |
| Atropine Sulfate | Atropine Sulfate | 14 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 14 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 14 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 14 | suppressed |
| Gemfibrozil | Gemfibrozil | 14 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 14 | suppressed |
| Lanthanum Carbonate | Lanthanum Carbonate | 14 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | 13 |
| Prednisolone Acetate | Prednisolone Acetate | 14 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | suppressed |
| Fluorometholone | Fluorometholone | 13 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 13 | suppressed |
| Lubiprostone | Lubiprostone | 13 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 13 | suppressed |
| Methotrexate | Methotrexate Sodium | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Pentoxifylline | Pentoxifylline | 13 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 12 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Letrozole | Letrozole | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Neomycin-Polymyxin-Gramicidin | Neomycin/Polymyxn B/Gramicidin | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 12 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Risperidone Er | Risperidone Microspheres | 12 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 12 | suppressed |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Acetazolamide | Acetazolamide | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 11 | suppressed |
| Humalog Mix 75-25 | Insulin Lispro Protamin/Lispro | 11 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 11 | suppressed |
| Lumigan | Bimatoprost | 11 | suppressed |
| Methimazole | Methimazole | 11 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 11 | suppressed |
| Ofloxacin | Ofloxacin | 11 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 11 | suppressed |
| Risperidone Odt | Risperidone | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $341.65 · 17 records | Neurocrine BioSciences, Inc. | COBENFY, GVOKE HYPOPEN, INGREZZA, KISUNLA, Kerendia, NUPLAZID, REPATHA, REXULTI, VYVGART HYTRULO, XIFAXAN | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with E.R. Squibb & Sons, L.L.C.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error